🎉 M&A multiples are live!
Check it out!

Liaoning Chengda Biotech Valuation Multiples

Discover revenue and EBITDA valuation multiples for Liaoning Chengda Biotech and similar public comparables like AstraZeneca India, CSL, and GSK India.

Liaoning Chengda Biotech Overview

About Liaoning Chengda Biotech

Liaoning Chengda Biotechnology Co Ltd is engaged in the research and development, production and sales of human vaccines.


Founded

2002

HQ

China
Employees

n/a

Website

cdbio.cn

Financials

LTM Revenue $237M

LTM EBITDA $68.1M

EV

$701M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Liaoning Chengda Biotech Financials

Liaoning Chengda Biotech has a last 12-month revenue of $237M and a last 12-month EBITDA of $68.1M.

In the most recent fiscal year, Liaoning Chengda Biotech achieved revenue of $241M and an EBITDA of $96.9M.

Liaoning Chengda Biotech expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Liaoning Chengda Biotech valuation multiples based on analyst estimates

Liaoning Chengda Biotech P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $241M $231M XXX XXX XXX
Gross Profit $258M $218M XXX XXX XXX
Gross Margin 107% 94% XXX XXX XXX
EBITDA $96.9M $64.8M XXX XXX XXX
EBITDA Margin 40% 28% XXX XXX XXX
Net Profit $123M $98.4M XXX XXX XXX
Net Margin 51% 43% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Liaoning Chengda Biotech Stock Performance

As of April 15, 2025, Liaoning Chengda Biotech's stock price is CNY 25 (or $3).

Liaoning Chengda Biotech has current market cap of CNY 10.4B (or $1.4B), and EV of CNY 5.1B (or $701M).

See Liaoning Chengda Biotech trading valuation data

Liaoning Chengda Biotech Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$701M $1.4B XXX XXX XXX XXX $0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Liaoning Chengda Biotech Valuation Multiples

As of April 15, 2025, Liaoning Chengda Biotech has market cap of $1.4B and EV of $701M.

Liaoning Chengda Biotech's trades at 3.0x LTM EV/Revenue multiple, and 10.3x LTM EBITDA.

Analysts estimate Liaoning Chengda Biotech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Liaoning Chengda Biotech and 10K+ public comps

Liaoning Chengda Biotech Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $701M XXX XXX XXX
EV/Revenue 3.0x XXX XXX XXX
EV/EBITDA 10.8x XXX XXX XXX
P/E 31.2x XXX XXX XXX
P/E/Growth 1.6x XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Liaoning Chengda Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Liaoning Chengda Biotech Valuation Multiples

Liaoning Chengda Biotech's NTM/LTM revenue growth is 9%

Liaoning Chengda Biotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Liaoning Chengda Biotech's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Liaoning Chengda Biotech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Liaoning Chengda Biotech and other 10K+ public comps

Liaoning Chengda Biotech Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -4% XXX XXX XXX XXX
EBITDA Margin 28% XXX XXX XXX XXX
EBITDA Growth -33% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 37% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 17% XXX XXX XXX XXX
G&A Expenses to Revenue 4% XXX XXX XXX XXX
R&D Expenses to Revenue 13% XXX XXX XXX XXX
Opex to Revenue 50% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Liaoning Chengda Biotech Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Liaoning Chengda Biotech M&A and Investment Activity

Liaoning Chengda Biotech acquired  XXX companies to date.

Last acquisition by Liaoning Chengda Biotech was  XXXXXXXX, XXXXX XXXXX XXXXXX . Liaoning Chengda Biotech acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Liaoning Chengda Biotech

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Liaoning Chengda Biotech

When was Liaoning Chengda Biotech founded? Liaoning Chengda Biotech was founded in 2002.
Where is Liaoning Chengda Biotech headquartered? Liaoning Chengda Biotech is headquartered in China.
Is Liaoning Chengda Biotech publicy listed? Yes, Liaoning Chengda Biotech is a public company listed on SHG.
What is the stock symbol of Liaoning Chengda Biotech? Liaoning Chengda Biotech trades under 688739 ticker.
When did Liaoning Chengda Biotech go public? Liaoning Chengda Biotech went public in 2021.
Who are competitors of Liaoning Chengda Biotech? Similar companies to Liaoning Chengda Biotech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Liaoning Chengda Biotech? Liaoning Chengda Biotech's current market cap is $1.4B
What is the current revenue of Liaoning Chengda Biotech? Liaoning Chengda Biotech's last 12-month revenue is $237M.
What is the current EBITDA of Liaoning Chengda Biotech? Liaoning Chengda Biotech's last 12-month EBITDA is $68.1M.
What is the current EV/Revenue multiple of Liaoning Chengda Biotech? Current revenue multiple of Liaoning Chengda Biotech is 3.0x.
What is the current EV/EBITDA multiple of Liaoning Chengda Biotech? Current EBITDA multiple of Liaoning Chengda Biotech is 10.3x.
What is the current revenue growth of Liaoning Chengda Biotech? Liaoning Chengda Biotech revenue growth between 2023 and 2024 was -4%.
Is Liaoning Chengda Biotech profitable? Yes, Liaoning Chengda Biotech is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.